Skip to Content
Merck
CN
All Photos(1)

Documents

Y0001533

Praziquantel for system suitability

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Praziquantel, 2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C19H24N2O2
CAS Number:
55268-74-1
Molecular Weight:
312.41
Beilstein:
761557
MDL number:
MFCD00058531
UNSPSC Code:
41116107
PubChem Substance ID:
329831478
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

praziquantel

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

O=C1CN(CC2N1CCc3ccccc23)C(=O)C4CCCCC4

InChI

1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2

InChI key

FSVJFNAIGNNGKK-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Praziquantel for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

P2670000

Praziquantel, European Pharmacopoeia (EP) Reference Standard

PHR1391

Praziquantel, Pharmaceutical Secondary Standard; Certified Reference Material

1554658

Praziquantel Related Compound A, United States Pharmacopeia (USP) Reference Standard

1554603

Praziquantel, United States Pharmacopeia (USP) Reference Standard

1554669

Praziquantel Related Compound B, United States Pharmacopeia (USP) Reference Standard

1554670

Praziquantel Related Compound C, United States Pharmacopeia (USP) Reference Standard

PHR2961

Praziquantel Related Compound A, pharmaceutical secondary standard, certified reference material

PHR2962

Praziquantel Related Compound B, pharmaceutical secondary standard, certified reference material

PHR2963

Praziquantel Related Compound C, pharmaceutical secondary standard, certified reference material

Hazard Statements

H412

Precautionary Statements

P273

Hazard Classifications

Aquatic Chronic 3

WGK

WGK 1

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

M J Doenhoff et al.
Parasitology, 136(13), 1825-1835 (2009-03-14)
Treatment with praziquantel (PZQ) has become virtually the sole basis of schistosomiasis control in sub-Saharan Africa and elsewhere, and the drug is reviewed here in the context of the increasing rate that it is being used for this purpose. Attention
Jennifer Keiser et al.
PLoS neglected tropical diseases, 8(7), e2975-e2975 (2014-07-18)
Treatment and morbidity control of schistosomiasis relies on a single drug, praziquantel. Hence, there is a pressing need to develop additional therapeutics against schistosomiasis. The antimalarial drug mefloquine shows antischistosomal activity in animal models and clinical trials, which calls for
Wei Wang et al.
Parasitology research, 111(5), 1871-1877 (2012-10-12)
Since praziquantel was developed in 1970s, it has replaced other antischistosomal drugs to become the only drug of choice for treatment of human schistosomiases, due to high efficacy, excellent tolerability, few and transient side effects, simple administration, and competitive cost.
Wei Wu et al.
Parasitology research, 112(3), 909-915 (2013-01-30)
Schistosomiasis remains a major public health problem with an estimated 200 million people infected in the world, and in China, schistosomiasis japonica is endemic in the south part of the country. In 1960s, before praziquantel was developed, there were about
J M Bygott et al.
Acta tropica, 111(2), 95-101 (2009-04-21)
The role of praziquantel in hydatid disease has not been well defined. This review evaluates the evidence on the use of praziquantel in treatment of cystic hydatid disease from in vitro and in vivo animal studies, human clinical studies and
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service